Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

Sosman JA, Unger JM, Liu PY, Flaherty LE, Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK, Southwest Oncology Group
J Clin Oncol. 2002 20 (8): 2067-75

PMID: 11956267 · DOI:10.1200/JCO.2002.08.072

MeSH Terms (14)

Adjuvants, Immunologic Adult Aged Aged, 80 and over Cancer Vaccines Disease-Free Survival Female Histocompatibility Antigens Class I Humans Male Melanoma Middle Aged Prospective Studies Skin Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: